ABSTRACT
BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of peripheral T-cell lymphoma. Patients usually present with splenomegaly and pancytopenia but without lymphadenopathy. Immunohistochemistry (IHC) staining of bone marrow biopsy shows intra-sinusoidal infiltration of CD3 and CD56 T-lymphocytes. Current treatment strategy of HSTCL includes a CHOP regimen (cyclophosphamide, adriamycine, vincristine, prednisone) followed by autologous transplantation. CASE: A 28-year-old male presented with abdominal fullness, weight loss, and massive splenomegaly. Laboratory findings revealed pancytopenia. A CT scan of the abdomen displayed hepatomegaly and massive splenomegaly. The bone marrow pathology examination showed monotonous medium-sized lymphocytes with some cluster of atypical lymphocytes with loosely condensed chromatin and pale cytoplasm. The intra-sinusoidal location was more prominent after using IHC staining of CD3 and CD56, which are characteristics of HSTCL. We administered CHOP-based regiment every 3 weeks for 3 cycles; however, the response was a stable disease. Since the splenomegaly was still massive and compromised the patient, the multidisciplinary team decided to perform splenectomy. Unfortunately, the patient did not survive the surgery. CONCLUSION: Hepatosplenic T-cell lymphoma is a rare aggressive disease, which is part of peripheral T-cell lymphoma. CHOP-based chemotherapy appeared to be ineffective, and we need further studies to find the optimal treatment of HSTCL.
Subject(s)
Liver Neoplasms , Lymphoma, T-Cell, Peripheral , Lymphoma, T-Cell , Pancytopenia , Splenic Neoplasms , Male , Humans , Adult , Splenomegaly/etiology , Splenomegaly/pathology , Pancytopenia/etiology , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/therapy , Lymphoma, T-Cell/diagnosis , Splenic Neoplasms/complications , Splenic Neoplasms/therapy , Liver Neoplasms/diagnosisABSTRACT
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.
Subject(s)
Endometrial Neoplasms , Societies, Medical , Child , Female , Humans , Asia , Endometrial Neoplasms/diagnosis , Medical OncologyABSTRACT
BACKGROUND: Intussusception in adults is considered a rare condition, accounting for 5% of all cases of intussusceptions and approx. 1-5% of bowel obstruction. Almost half intussusceptions of the bowel are associated with malignant disease; thus, we should also treat the underlying malignancy. CASE DESCRIPTION: A 52-year-old male presented with colicky right lower abdominal pain for a 6-month period. He had a weight loss of 20kg within 6 months. Physical examination revealed a tender right lower abdominal mass. Colonoscopy showed a mass that filled the ileocecal. The digestive surgeon performed laparoscopic right hemicolectomy with end-to-end anastomosis. Histopathology examination showed diffuse proliferation of large tumor cells with centroblastic-like features prominently in submucosal area, with normal epithelial mucosa. The immunohistochemistry result concluded the final dia-gnosis of diffuse large B-cell lymphoma. RCHOP chemotherapy regimens were administered every 3 weeks for 6 cycles. The response was complete remission. DISCUSSION: Intussusception was preoperatively dia-gnosed by multi-slice spiral CT scans with the characteristic target or sausage sign, edematous bowel wall and mesentery in the lumen. After surgery, approximately 90% of adult intussusception cases have a demonstrable etiology. Malignant lymphoma, especially diffuse large B-cell lymphoma, of the ileocecal is one cause of the adult intussusception. CONCLUSION: Adult bowel intussusception is a rare clinical entity. Abdominal CT is considered as the most sensitive imaging modality in the dia-gnosis of intussusception. Diffuse large B-cell lymphoma is the most common cause of ileocecal intussusception.
Subject(s)
Intussusception , Lymphoma, Large B-Cell, Diffuse , Adult , Anastomosis, Surgical/adverse effects , Colonoscopy/adverse effects , Humans , Intussusception/diagnosis , Intussusception/etiology , Intussusception/surgery , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Tomography, X-Ray Computed/adverse effectsABSTRACT
Chronic Myeloid Leukemia (CML) is one of the myeloproliferative disorders characterized by Philadelphia chromosome presence. Contrary to Western countries, most CML patients in Indonesia present symptoms with splenomegaly as the most common finding. It is rare to find asymptomatic CML patients. We present a case of asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL (+) without splenomegaly who achieved a hematologic and molecular response to imatinib.
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Leukemia, Myeloid, Chronic-Phase , Fusion Proteins, bcr-abl/genetics , Humans , Imatinib Mesylate/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myeloid, Chronic-Phase/diagnosis , Leukemia, Myeloid, Chronic-Phase/drug therapy , Splenomegaly/etiologyABSTRACT
BACKGROUND: Primary breast lymphoma is a rare disease and accounts for 0.4-0.5% of malignant breast neoplasms and 1.7-2.2% of extra-nodal lymphomas, with diffuse large B-cell lymphoma (DLBCL) as the most common histologic subtype. CASE: A 47-year-old female with beta thalassemia presented with a lump of the left breast, redness, pain, and swelling of her left breast. Physical examination showed tender, red, swollen left breast. Laboratory findings show mild anemia and normal level of lactate dehydrogenase 329 U/L (normal range: 240-480 U/L). PET scan showed hypermetabolic mass with irregular margins covering the whole left breast quadrants with the size of 11.25 x 5.17cm with left pectoralis major, left parasternal, and left axillary hypermetabolic nodules. Histopathology and immunohistochemistry staining showed a non-germinal center B-cell-like subtype of DLBCL CD20+. We administered the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison) every 3 weeks for 6 cycles. The response was complete remission. The patient tolerated the chemotherapy well and achieved long term complete remission. CONCLUSION: Primary breast lymphoma is a rare disease with the most common subtype is diffuse large B-cell lymphoma. Systemic chemother-apy R-CHOP is the treatment option for primary breast diffuse large B-cell lymphoma.